What is Elpiscience Biopharma?
Elpiscience Biopharma is a clinical-stage biopharmaceutical company dedicated to the innovation and development of cutting-edge cancer immunotherapies. Established in 2017 and headquartered in Shanghai, China, the company is strategically positioned to address unmet needs in oncology. Its focus on novel therapeutic approaches aims to harness the power of the immune system to combat various forms of cancer, marking it as a key player in the rapidly evolving field of immuno-oncology.
How much funding has Elpiscience Biopharma raised?
Elpiscience Biopharma has raised a total of $225M across 3 funding rounds:
Series A
$20M
Series B
$100M
Series C
$105M
Series A (2017): $20M with participation from Lilly Asia Ventures
Series B (2019): $100M led by Hyfinity Investments
Series C (2021): $105M supported by Greater Bay Area Homeland Development Fund, Superstring Capital, Maison Capital, Cormorant Asset Management, and Pluto Connection Limited
Key Investors in Elpiscience Biopharma
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm with offices in Shanghai, Hong Kong, and Palo Alto, California, focused on building companies that develop breakthrough products to treat diseases and improve human health.
Cormorant Asset Management
Cormorant Asset Management is a life sciences investment firm founded in 2013, providing financial resources to innovative publicly traded and private companies in biotech and allied sectors.
Maison Capital
Maison Capital is an investment firm emphasizing long-term perspectives and in-depth research, focusing on creating wealth and improving quality of life. They are involved in various investment activities and highlight their commitment to social responsibility and industry partnerships.
What's next for Elpiscience Biopharma?
With the recent infusion of capital, Elpiscience Biopharma is poised for accelerated growth and the advancement of its clinical programs. The enterprise-level backing suggests a strategic focus on scaling operations, expanding research and development initiatives, and potentially preparing for later-stage clinical trials or commercialization efforts. This significant investment will likely fuel the company's mission to bring transformative cancer treatments to patients worldwide, reinforcing its trajectory as a leader in biopharmaceutical innovation.
See full Elpiscience Biopharma company page
